Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.44 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.44 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.44 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 2/20 | 0.35 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956090 | 1.00 | CA1 (0.59) | CA1CA2CYP1A2CYP2A6ORAI1 | |
| SCHEMBL17728163 | 0.93 | CA1 (0.61) | CA1CA2CYP1A2CYP2A6ORAI1 | |
| SCHEMBL29951274 | 0.93 | CA1 (0.61) | CA1CA2CYP1A2CYP2A6ORAI1 | |
| SCHEMBL28784898 | 0.86 | CA2 (0.76) | CA1CA2ENPP2MGLLTTR | |
| SCHEMBL13667343 | 0.79 | CA2 (0.73) | CA1CA2ENPP2TTRTSHR | |
| SCHEMBL205203 | 0.78 | CA2 (0.80) | CA1CA2ENPP2TTRTSHR | |
| SCHEMBL31354846 | 0.78 | CA2 (0.80) | CA1CA2ENPP2TTRTSHR | |
| SCHEMBL29936739 | 0.78 | CYP1A2 (0.72) | CYP1A2CYP2A6BACE1TSHR | |
| SCHEMBL6564751 | 0.78 | CYP1A2 (0.72) | CYP1A2CYP2A6BACE1TSHR | |
| SCHEMBL3678771 | 0.76 | CA1 (0.61) | CA1CA2CYP1A2ENPP2TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11566016-B2 | MAP kinase modulators and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-31 | — | — | US | disclosed |
| US-20220009905-A1 | MAP KINASE MODULATORS AND USES THEREOF | NORTHWESTERN UNIVERSITY | 2022-01-13 | — | — | US | disclosed |
| US-11149020-B2 | MAP kinase modulators and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-10-19 | — | — | US | disclosed |
| US-10428047-B2 | MAP kinase modulators and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-10-01 | — | — | US | disclosed |
| US-20170369472-A1 | MAP KINASE MODULATORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-12-28 | — | — | US | disclosed |
| US-9783525-B2 | Map kinase modulators and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160130253-A1 | MAP KINASE MODULATORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2016-05-12 | — | — | US | disclosed |
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-27 | — | — | US | disclosed |
| EP-1506190-B1 | (IMIDAZOL-1-YL-METHYL)-PYRIDAZINE AS NMDA RECEPTOR BLOCKER | HOFFMANN LA ROCHE (CH) | 2006-06-14 | — | — | EP | disclosed |
| US-7005432-B2 | Substituted imidazol-pyridazine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2006-02-28 | — | — | US | disclosed |
| EP-1506190-A1 | (IMIDAZOL-1-YL-METHYL)-PYRIDAZINE AS NMDA RECEPTOR BLOCKER | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-16 | — | — | EP | disclosed |
| US-20030229096-A1 | Substituted imidazol-pyridazine derivatives | EVOTEC INTERNATIONAL GMBH (DE) | 2003-12-11 | — | — | US | disclosed |
| WO-2003097637-A1 | (IMIDAZOL-1-YL-METHYL)-PYRIDAZINE AS NMDA RECEPTOR BLOCKER | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428047-B2 | MAP kinase modulators and uses thereof | MAPK1, MAP3K1, MAP3K2 | CA1 3578/4885CA2 3980/4885CYP1A2 4173/4885 |
| US-20160130253-A1 | MAP KINASE MODULATORS AND USES THEREOF | MAPK1, MAP3K1, MAP3K2 | CA1 3578/4885CA2 3980/4885CYP1A2 4173/4885 |
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | TFEB, PCK2, JAK2 | CA1 3816/4885CA2 1505/4885CYP1A2 2590/4885 |
| US-20170369472-A1 | MAP KINASE MODULATORS AND USES THEREOF | MAPK1, MAP3K1, MAP3K2 | CA1 3578/4885CA2 3980/4885CYP1A2 4173/4885 |
| US-11566016-B2 | MAP kinase modulators and uses thereof | MAPK1, MAP3K1, MAP3K2 | CA1 3578/4885CA2 3980/4885CYP1A2 4173/4885 |
| US-11149020-B2 | MAP kinase modulators and uses thereof | MAPK1, MAP3K1, MAP3K2 | CA1 3578/4885CA2 3980/4885CYP1A2 4173/4885 |
| US-20030229096-A1 | Substituted imidazol-pyridazine derivatives | GRIN2B, GRIN2A, GRIN2C | CA1 2980/4885CA2 1927/4885CYP1A2 1651/4885 |
| US-20220009905-A1 | MAP KINASE MODULATORS AND USES THEREOF | MAPK1, MAP3K1, MAP3K2 | CA1 3578/4885CA2 3980/4885CYP1A2 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.